Voyager taps Brammer and Fujifilm for gene therapy development program

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/daizuoxin)
(Image: Getty/daizuoxin)

Related tags: CDMO, Brammer Bio, Fujifilm diosynth biotechnologies, Gene therapy, Manufacturing

The clinical-stage gene therapy company Voyager Therapeutics has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to expand its manufacturing capabilities.

Voyager will transfer its research and development production capabilities to the contract development and manufacturing organizations (CDMOs), which will support the development of its gene therapy programs, providing late-stage clinical and commercial-scale capabilities.

Voyager will lead early-stage development and scale-up before transferring the technology. The company’s manufacturing platform uses a baculovirus/Sf9 cell production process to produce clinical and commercial scale batches of adeno-associated virus (AAV) vectors.

The length of the collaboration has not specifically been disclosed, though it could be renewed based on meeting set milestones and other criteria, a spokesperson told us.

"Voyager plans to use [the CDMOs] to support the clinical development of its programs and if its programs are approved, for commercial supply,"​ they added.

In line with the collaboration announcement, Voyager will partner with Brammer to implement a commercial-ready manufacturing process under current good manufacturing practice (cGMP) at its Cambridge facility. At this facility and others, Brammer recently has completed a series of expansions​ as part of its three-year, $200m investment program.

Voyager also will partner with Fujifilm​ to provide first-in-human (FIH) cGMP clinical trial material production capacity at the CDMO’s College Station facility in Texas.

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us


View more